Laripronte is a combination drug with antimicrobial, mucolytic, anti-inflammatory and antiviral effects.
Release form and composition
Laripronte is produced in the form of lozenges (10 pieces in blisters or blister packs, 2 blisters each or in a carton box).
The composition of 1 tablet contains the active substances:
- Lysozyme hydrochloride - 10 mg;
- Dequalinium chloride - 0.25 mg.
Indications for use
Laripront is prescribed for the treatment of bacterial and fungal infectious and inflammatory diseases of the oral cavity, larynx and pharynx, including pharyngitis, stomatitis, sore throat, tonsillitis, laryngitis, thrush, etc.
Also, the drug is indicated before and after dental and ENT operations.
The use of Laripronte is contraindicated in the presence of hypersensitivity to the components of the drug.
Dosing and Administration
Laripronte accept inside, holding a tablet under language or in a mouth before full dissolution. Within 30 minutes after the use of the drug from the ingestion of food or liquids should refrain.
Single dose - 1 tablet. Laripront should be taken every 2-3 hours.
During therapy, there may be side effects, manifested in the form of allergic reactions.
Before starting the use of Laripront, as well as in cases of uncharacteristic symptoms, it is recommended to consult with your doctor.
Data on the interaction of Laripront with other drugs are not available.
Terms and conditions of storage
Keep out of reach of children at temperature up to 25 ° C.
Shelf life - 3 years.